Under construction – not a live service
Sign in
Taking people in ChileNo phase

Ischemic And Bleeding Risk Assessment After TAVR

Key facts

Where
Santiago, ChileSee the site

Where in Chile

  • Complejo Asistencial Dr. Sótero del RíoSantiago, ChileContact: Giuseppe Esposito, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Niguarda Hospital
Trial code
NCT06000943
Record updated
16 April 2026
Original description
Transcatheter aortic valve replacement (TAVR) represents an effective treatment to improve symptoms and prognosis in patients with symptomatic severe aortic stenosis (AS) (1-2).Read full original descriptionShow less

Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)

Transcatheter aortic valve replacement (TAVR) represents an effective treatment to improve symptoms and prognosis in patients with symptomatic severe aortic stenosis (AS) (1-2).

Giving an established uniform approach towards anticoagulation and antithrombotic therapy after TAVR in the post POPULAR-TAVI era, recent data coming from the analysis of different trials, highlight the relevance of the patient's background on the occurrence of ischemic and bleeding events.

Despite this a targeted antithrombotic strategy remains unexplored and all patients undergoing TAVR without other indication to DAPT or OAC, were currently treated according with the concept of "less is more" (only SAPT or only OAC) regardless the risk level (5-6).

The keys points of the project will be 1) the assessment of ischemic and bleeding risk after TAVR stratified according with antithrombotic therapy and surgical risk; 2) the evaluation of the impact of prostheses type and the complete blood count variables (hemoglobine and platelets) on the daily average ischemic and bleeding risk and 3) the evaluation of the dynamic therapeutic changes after TAVR during the follow up.

Inclusion: All patients with severe aortic stenosis undergoing TAVR; Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR.

Exclusion: Patients in triple antithrombotic therapy at discharge; Patients who died during the index procedure; Patients with a known prognosis less than 1 year at the time of TAVR.

ClinicalTrials.gov NCT06000943